Xention Limited Appoints Dr Keith McCullagh as New Chairman of its Board
XENTION LTD announced the appointment of Dr Keith McCullagh as the new non-executive Chairman of its Board of Directors.
Keith McCullagh is an experienced biotech entrepreneur. From 2003 until his retirement last year he was CEO of Santaris Pharma, the Danish RNA medicines company. From 2000 to 2003 he was the founding chairman of OnMedica Group plc, a European pharmaceutical e-detailing business. Also, in 2000 Keith co-founded Pharmacy 2U Ltd, a UK warehouse and mail order pharmacy, of which he remains non-executive chairman. From 1986 to 1998 Keith was Chief Executive of British Biotech plc, a company he founded and which was the first bioscience research company to be listed on the London Stock Exchange. Prior to British Biotech, Keith was UK Director of Research for GD Searle & Co. In addition to Xention, he is currently Chairman of Affitech AS and Pharmacy 2U Ltd and a director of Santaris Pharma A/S. He holds a veterinary sciences degree from the University of Bristol and a PhD in pathology from the University of Cambridge.
David Ebsworth, who is stepping down as Chairman, will remain on the board as a non-executive director.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
